Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that inhibiting EGFR and MEK in hair follicles may lead to a partial collapse of the immune privilege in the follicles and increased secretion of IL-33.

In this study, the researchers found that constitutive activation of the EGFR in mice led to increased sebum production, enlarged sebaceous glands, and altered gene expression related to sebocyte proliferation and lipogenesis.

This review discusses Amphiregulin (AREG) as a potential target for treating fibrotic disorders and cancer, highlighting its role in disease progression and promising results in preclinical studies and early trials.

Certain gene variations in EGF and EGFR may increase the risk of alopecia areata in Koreans.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

In this study, researchers reported that a keratinocyte growth factor-Ig fusion protein could specifically detect and localize KGFRs in epithelial tissues, suggesting a method for histochemical detection of growth factor receptors.

In this study, the researchers found that EGF and EGFR play crucial roles in goat fetal skin development, with their expression increasing progressively during gestation.

This case report describes a patient with non-small cell lung cancer who experienced trichomegaly (excessive eyelash growth) as a side effect of erlotinib treatment without developing typical skin rash.

This article reviews eyelash elongation as a side effect of EGFR inhibitors in cancer treatment, finding that the condition is typically not severe and may be managed by trimming.

Fgfr2b helps maintain healthy skin and prevent cancer.

This study observed that the expression of EGF and EGFR increased during goat fetal skin development, suggesting these components play significant roles in skin maturation.

This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.

This review discusses common cutaneous reactions to targeted cancer drugs such as tyrosine kinase inhibitors and reports no new clinical results.

This review discusses the clinical characteristics of alopecia in cancer patients, highlighting its potential role as an associated finding or diagnostic clue, but reports no new clinical results.

This review covers various skin-related adverse drug reactions and lists common drugs associated with these reactions but presents no new clinical findings.

This article discusses the emerging field of supportive oncodermatology, which collaborates between oncology and dermatology to address skin-related side effects of cancer treatments, and reports no new clinical results.

Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.

This narrative review provides an overview of the persistent dermatological side effects experienced by cancer survivors due to treatments, highlighting their impact on quality of life and the need for structured dermatological care during survivorship.

This review discusses the therapeutic potential and safety of bioidentical recombinant human epidermal growth factor (rhEGF) for various skin and mucosa conditions and reports no new clinical results.

In this study, deleting the Igf1 receptor in specific skin cells of mice affected hair follicle cycling but not overall skin health, suggesting Igf1r's role in hair cycle regulation through Bmp-4 activation.

This study reports that EGF at specific concentrations promotes the proliferation and migration of hair follicle ORS cells by activating the Wnt/β-catenin signaling pathway in vitro.

This systematic review describes current findings on the use of recombinant epidermal growth factor (rhEGF) for skin aging and wound healing, emphasizing its potential benefits but highlighting the need for more controlled studies to optimize dosing and treatment protocols.

This case report observed that terminal hair growth on the nose tip was associated with gefitinib treatment in a 65-year-old woman with lung adenocarcinoma.

This study found that bursts of ERK activation in the epidermis of mice were linked to cell division, supporting synchronized cell proliferation and transient ERK activity in living tissues.

This study found that in mutant NRAS melanoma, MEK inhibitors led to increased AKT signaling and reduced MIG6, a change that may enhance cell migration and invasiveness.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

This review discusses skin-related toxicities associated with targeted cancer therapies and emphasizes the need for dermatologists to understand and manage these adverse effects, but reports no new experimental results.

This review discusses various adverse drug reactions affecting the skin, hair, and nails, emphasizing the importance of recognizing and reporting these reactions but reports no new clinical findings.